Bristol-Myers Squibb Co. BMY
$62.84
-1.19%
at last close
Market Cap$129.92 billion
P/E Ratio13.84
Div Yield4.01%
Volume12.21M
52-Week Range
$42.52$68.64
Analyst Ratings
- Consensus
- Moderate Buy — 9 Buy · 7 Hold · 1 Sell (17 analysts)
- Avg. Price Target
- $65.76 (+4.7% upside)
Key Stats
- Today's Range
- $62.52 – $64.35
- 50-Day Range
- $56.78 – $68.64
- 52-Week Range
- $42.52 – $68.64
- Volume
- 12.21 million shs
- Average Volume
- 8.25 million shs
- Market Cap
- $129.92 billion
- P/E Ratio
- 13.84
- Dividend Yield
- 4.01%
Valuation
- P/E Ratio
- 13.84
- Price / Book
- 5.82
- Price / Sales
- 2.64
Dividend
- Dividend Yield
- 4.01%
- Annual Dividend
- $2.52
- Payout Ratio
- 55.51%
- Ex-Dividend Date
- 2026-10-02
Short Interest
- Short Interest
- 0.39%
- Days to Cover
- 1.64
Financials (TTM)
- Revenue
- $49.19 billion
- Net Income
- $9.27 billion
- Net Margin
- 18.85%
- Return on Equity
- 41.55%
- Debt-to-Equity
- 1.92
About Bristol-Myers Squibb Co.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Related Stocks
Compare head-to-head: BMY vs LLY·BMY vs JNJ·BMY vs ABBV·BMY vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.